The value of monitoring (subclinical) donor specific antibodies (DSAs) for kidney transplant outcomes

DSAs are associated with antibody mediated casu quo chronic rejection and poor outcome. The value of a DSA as biomarker for ABMR diagnosis from an indication biopsy (increased creatinine and proteinuria) seems clear. However, the value of subclinical DSAs (without increase in serum creatinine or proteinuria) is less clear.

Subclinical DSAs are thought be an early biomarker of nonadherence or rejection but may also be transient around other clinical issues. The merit of detecting early rejection from routine DSA monitoring is uncertain, as are potential treatment options and change in prognosis. Subsequently, there is clinical practice variation in routine monitoring of DSAs.

Topic Chair: Aiko de Vries

Topic Steering Committee: Marie Paule Emonds, Soufian Meziyerh, Emanuele Cozzi, Dominique Bertrand, Dennis van den Broek, Klemens Budde, Anthony Dorling, Covadonga López del Moral